IgG N-Glycosylation Is Altered in Coronary Artery Disease

Coronary artery disease (CAD) is the most common cardiovascular disease, and previous studies have shown a significant association between N-glycosylation and the development of atherosclerotic plaques. Genos LtdSveučilište u Rijeci / University of Rijeka and University of Zagreb/Sveuciliste u Zagrebu teamed up to determine whether the N-glycome of immunoglobulin G is associated with the disease as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response.
The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD. The obtained data provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
Barbara RadovaniFrano VučkovićAldo Pietro Maggioni, Ele Ferrannini, Gordan Lauc and Ivan Gudelj

See the full article here

Disease management to disease modification – removing plaque to undo atherosclerosis

You can read a great interview with folks from Cyclarity Therapeutics at Longevity.Technology. Since they are one of the few companies developing tailor-made CDs to tackle a major disease, this is certainly worth attention.
“Cyclarity’s approach to true disease medication, and therefore reversal of age-related disease, without doubt, offers a great deal of promise for investors, for healthcare systems in the US and globally, and most of all for those affected by the atherosclerosis-related disease.
. . . this may be the perfect opportunity for Cyclarity to enter the field, as it is one of the few solutions available that addresses the limiting factors of previous therapies both from a scientific perspective and from a market perspective.”

See the full article here

Beren Awarded Expedited Roadmap for Treatment of Homozygous Familial Hypercholesterolemia

Fascinating news from Beren Therapeutics:
Beren Awarded Expedited Roadmap for Treatment of Homozygous Familial Hypercholesterolemia
Beren’s novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP), for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia. The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases.
“We are excited to begin work under ILAP and look forward to collaborating with other regulators, payors, and governments to expedite the development and identify and remove access barriers.” – commented Jason Camm, CEO. Jules Payne from HEART UK – The Cholesterol Charity added that “Significant unmet needs remain, and with this advancement, we are hopeful for a new treatment option that can truly alter the course of the disease for the children and patients living with HoFH.”
Beren Therapeutics, P.B.C. is currently in stealth.

See the full article here

Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis

The cyclodextrin-supported atherosclerosis treatment field is getting crowded. Here is a unique approach using polyethylene glycol succinate (TPGS)-CD, which was adsorbed on rHDL, then modified with Apo-Ai, and coated with hyaluronan to obtain HT-rHDL. Piece of cake!
China Pharmaceutical University

Full article on ScienceDirect

cholesterol, carbohyde